CY1119818T1 - Χρηση του αναστολεα c1 για την προληψη βλαβης ισχαιμιας-επαναιματωσης - Google Patents
Χρηση του αναστολεα c1 για την προληψη βλαβης ισχαιμιας-επαναιματωσηςInfo
- Publication number
- CY1119818T1 CY1119818T1 CY20181100029T CY181100029T CY1119818T1 CY 1119818 T1 CY1119818 T1 CY 1119818T1 CY 20181100029 T CY20181100029 T CY 20181100029T CY 181100029 T CY181100029 T CY 181100029T CY 1119818 T1 CY1119818 T1 CY 1119818T1
- Authority
- CY
- Cyprus
- Prior art keywords
- inhibitor
- reperfusion
- ischemical
- prevent
- recurrent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με τη θεραπευτική και προφυλακτική χρήση του αναστολέα C1 για την πρόληψη, μείωση και θεραπεία της βλάβης ισχαιμίας και επαναιμάτωσης. Ο αναστολέας C1 της παρούσας εφεύρεσης εξακολουθεί να είναι θεραπευτικώς αποτελεσματικός, όταν χορηγείται μετά από μια ισχαιμική περίοδο και επαναιμάτωση και επομένως είναι ιδιαίτερα χρήσιμος για απρόβλεπτες εμφανίσεις ισχαιμικής επαναιμάτωσης, όπως π.χ. ένα εγκεφαλικό επεισόδιο.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05112630 | 2005-12-21 | ||
US76094406P | 2006-01-23 | 2006-01-23 | |
EP06824316A EP1965831B1 (en) | 2005-12-21 | 2006-12-19 | Use of c1 inhibitor for the prevention of ischemia-reperfusion injury |
EP11172880.4A EP2380587B1 (en) | 2005-12-21 | 2006-12-19 | Use of C1 inhibitor for the prevention of ischemia-reperfusion injury |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119818T1 true CY1119818T1 (el) | 2018-06-27 |
Family
ID=38016640
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100950T CY1112452T1 (el) | 2005-12-21 | 2011-10-05 | Χρηση του αναστολεα c1 για την προληψη της βλαβης εξ ισχαιμιας-επαναιματωσης |
CY20181100029T CY1119818T1 (el) | 2005-12-21 | 2018-01-10 | Χρηση του αναστολεα c1 για την προληψη βλαβης ισχαιμιας-επαναιματωσης |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100950T CY1112452T1 (el) | 2005-12-21 | 2011-10-05 | Χρηση του αναστολεα c1 για την προληψη της βλαβης εξ ισχαιμιας-επαναιματωσης |
Country Status (15)
Country | Link |
---|---|
US (3) | US8071532B2 (el) |
EP (2) | EP2380587B1 (el) |
JP (2) | JP5394748B2 (el) |
KR (1) | KR101508668B1 (el) |
AT (1) | ATE516043T1 (el) |
AU (1) | AU2006327989B2 (el) |
CA (1) | CA2632400C (el) |
CY (2) | CY1112452T1 (el) |
DK (1) | DK2380587T3 (el) |
HR (2) | HRP20110622T1 (el) |
IL (2) | IL192180A (el) |
NZ (1) | NZ568749A (el) |
PL (2) | PL1965831T3 (el) |
SI (1) | SI2380587T1 (el) |
WO (1) | WO2007073186A2 (el) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2502539A1 (en) * | 2002-10-17 | 2004-04-29 | Pharming Intellectual Property B.V. | Protein modification |
PL1965831T3 (pl) | 2005-12-21 | 2011-12-30 | Pharming Intellectual Property B V | Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego |
EP3028716B1 (en) * | 2006-10-10 | 2020-09-16 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
JP5423266B2 (ja) * | 2009-09-14 | 2014-02-19 | 富士電機株式会社 | デジタル制御スイッチング電源装置 |
EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
CA2829037C (en) * | 2011-03-09 | 2022-05-17 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
ES2714999T3 (es) | 2011-09-24 | 2019-05-31 | Csl Behring Gmbh | Terapia de combinación que usa inmunoglobulina e inhibidor de C1 |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
JP6127063B2 (ja) * | 2011-12-22 | 2017-05-10 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 中枢神経系の続発性浮腫の治療のためのc1インヒビターの使用 |
WO2014008242A1 (en) * | 2012-07-03 | 2014-01-09 | The Trustees Of Columbia University In The City Of New York | The use of interleukin-11 to protect against ischemia and reperfusion injury |
WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
GB2509260B (en) | 2012-11-02 | 2016-05-04 | True North Therapeutics Inc | Anti-complement C1s antibodies and uses thereof |
ES2609070T3 (es) * | 2013-02-28 | 2017-04-18 | Csl Behring Gmbh | Agente terapéutico para el embolismo de líquido amniótico |
EP2964255B1 (en) * | 2013-03-08 | 2020-11-04 | CSL Behring GmbH | Treatment and prevention of remote ischemia-reperfusion injury |
EP2968434B1 (en) | 2013-03-15 | 2017-06-28 | Shire Viropharma Incorporated | C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae). |
EP3013366B1 (en) * | 2013-06-28 | 2021-08-25 | CSL Behring GmbH | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
ES2788697T3 (es) * | 2014-11-03 | 2020-10-22 | Thrombolytic Science Llc | Métodos y composiciones para trombólisis segura y eficaz |
US10729767B2 (en) | 2015-04-06 | 2020-08-04 | Bioverativ Usa Inc. | Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage |
WO2016196070A1 (en) | 2015-06-03 | 2016-12-08 | Children's Hospital Medical Center | Compositions and methods for treating neonatal biliary atresia |
JP7189767B2 (ja) * | 2015-11-19 | 2022-12-14 | 武田薬品工業株式会社 | 組換えヒトc1エステラーゼインヒビター及びその使用 |
CN109562149A (zh) | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
AU2017316513A1 (en) | 2016-08-23 | 2019-03-28 | Csl Behring Gmbh | Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency |
US11154596B2 (en) | 2017-06-16 | 2021-10-26 | Thrombolytic Science, Llc | Methods for thrombolysis |
CA3075686A1 (en) | 2017-09-15 | 2019-03-21 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
EP3758739B1 (en) | 2018-02-28 | 2024-05-15 | Pharming Intellectual Property B.V. | Treatment and prevention of pre-eclampsia |
JP2022505307A (ja) | 2018-10-17 | 2022-01-14 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | C1-inhを精製する方法 |
US20220363715A1 (en) | 2019-07-04 | 2022-11-17 | Csl Behring Gmbh | Process for Purifying C1-INH |
KR102191500B1 (ko) | 2020-03-30 | 2020-12-15 | 국립낙동강생물자원관 | 초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
KR102217607B1 (ko) | 2020-06-01 | 2021-02-18 | 국립낙동강생물자원관 | 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
KR102191452B1 (ko) | 2020-06-30 | 2020-12-15 | 주식회사 에이치비헬스케어 | 곶감 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
CA3198740A1 (en) | 2020-11-20 | 2022-05-27 | John Roberts | Method for treating antibody-mediated rejection |
EP4366761A1 (en) | 2021-07-09 | 2024-05-15 | Pharming Intellectual Property B.V. | Using c1 esterase inhibitor to treat viral infection-related symptoms |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1402897E (pt) | 1999-05-14 | 2007-01-31 | Jens Christian Jensenius | Novas indicações de lectina de ligação a manana (mbl) no tratamento de indivíduos imunocomprometidos |
US7067713B2 (en) * | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
JP2003521914A (ja) * | 2000-01-31 | 2003-07-22 | ファーミング インテレクチュアル プロパティー ベー.フェー. | トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター |
JP2004100982A (ja) * | 2002-09-05 | 2004-04-02 | Denso Corp | 熱交換器 |
CA2502539A1 (en) * | 2002-10-17 | 2004-04-29 | Pharming Intellectual Property B.V. | Protein modification |
PL1626736T3 (pl) * | 2003-05-16 | 2021-05-04 | Pharming Intellectual Property B.V. | Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego |
PL1965831T3 (pl) | 2005-12-21 | 2011-12-30 | Pharming Intellectual Property B V | Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego |
-
2006
- 2006-12-19 PL PL06824316T patent/PL1965831T3/pl unknown
- 2006-12-19 AT AT06824316T patent/ATE516043T1/de active
- 2006-12-19 US US12/158,987 patent/US8071532B2/en active Active
- 2006-12-19 EP EP11172880.4A patent/EP2380587B1/en active Active
- 2006-12-19 SI SI200632219T patent/SI2380587T1/en unknown
- 2006-12-19 JP JP2008547134A patent/JP5394748B2/ja active Active
- 2006-12-19 NZ NZ568749A patent/NZ568749A/en unknown
- 2006-12-19 AU AU2006327989A patent/AU2006327989B2/en active Active
- 2006-12-19 PL PL11172880T patent/PL2380587T3/pl unknown
- 2006-12-19 KR KR1020087017880A patent/KR101508668B1/ko active IP Right Grant
- 2006-12-19 CA CA2632400A patent/CA2632400C/en active Active
- 2006-12-19 EP EP06824316A patent/EP1965831B1/en active Active
- 2006-12-19 DK DK11172880.4T patent/DK2380587T3/en active
- 2006-12-19 WO PCT/NL2006/050321 patent/WO2007073186A2/en active Application Filing
-
2008
- 2008-06-15 IL IL192180A patent/IL192180A/en active IP Right Grant
-
2011
- 2011-08-25 HR HR20110622T patent/HRP20110622T1/hr unknown
- 2011-10-05 CY CY20111100950T patent/CY1112452T1/el unknown
- 2011-10-11 US US13/271,107 patent/US8415288B2/en active Active
-
2013
- 2013-02-04 JP JP2013019186A patent/JP2013126992A/ja active Pending
- 2013-02-25 US US13/776,529 patent/US9211318B2/en active Active
- 2013-10-17 IL IL228954A patent/IL228954A/en active IP Right Grant
-
2017
- 2017-11-13 HR HRP20171738TT patent/HRP20171738T1/hr unknown
-
2018
- 2018-01-10 CY CY20181100029T patent/CY1119818T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119818T1 (el) | Χρηση του αναστολεα c1 για την προληψη βλαβης ισχαιμιας-επαναιματωσης | |
MX2009005185A (es) | Analogos de tiofeno para el tratamiento o prevencion de infecciones de flavivirus. | |
SMP200900013B (it) | Peptidomimetici smac utili come inibitori di iap | |
NO20072665L (no) | Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser | |
UA101943C2 (ru) | Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления | |
IN2014DN08578A (el) | ||
GEP20125683B (en) | Serine proteases inhibitors for hcv infections treatment | |
NO20081846L (no) | Bifenylderivater og deres anvendelse ved behandling av hepatitt C | |
NO20083032L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av mani og bipolar forstyrrelse | |
NO20083036L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon | |
EA200602220A1 (ru) | Новое применение пептидных соединений для лечения амиотрофического бокового склероза | |
NO20074275L (no) | 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister | |
NZ716598A (en) | Anthelmintic compounds and compositions and method of using thereof | |
MY145823A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity | |
CO5570674A2 (es) | Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos | |
WO2009055335A3 (en) | Hcv protease inhibitors | |
MY149175A (en) | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents | |
ATE384058T1 (de) | Thiazolderivate | |
ATE531377T1 (de) | Purin-derivate und anwendungsverfahren | |
NZ598750A (en) | Therapeutic agent for mood disorders | |
TN2011000204A1 (en) | Cycloundecadepsipeptide compounds and use of said compounds as a medicament | |
WO2009148600A3 (en) | Deuterated lysine-based compounds | |
NZ598754A (en) | Therapeutic agent for anxiety disorders | |
WO2009041026A1 (ja) | Cxcl10産生抑制剤 | |
WO2008130632A3 (en) | Methods of increasing camp levels and uses thereof |